The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 21, 2013
Filed:
Aug. 13, 2009
Piotr Bobrowicz, Hanover, NH (US);
Stephen R. Hamilton, Enfield, NH (US);
Tillman U. Gerngross, Hanover, NH (US);
Stefan Wildt, Lebanon, NH (US);
Byung-kwon Choi, Norwich, NH (US);
Juergen Hermann Nett, Grantham, NH (US);
Robert C. Davidson, Enfield, NH (US);
Piotr Bobrowicz, Hanover, NH (US);
Stephen R. Hamilton, Enfield, NH (US);
Tillman U. Gerngross, Hanover, NH (US);
Stefan Wildt, Lebanon, NH (US);
Byung-Kwon Choi, Norwich, NH (US);
Juergen Hermann Nett, Grantham, NH (US);
Robert C. Davidson, Enfield, NH (US);
Merck Sharp & Dohme, Rahway, NJ (US);
Abstract
The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII activity, which produce bisected N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.